Primo-indication
Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Intervention Type
Pharmaceutical
Solid/Hematological
Solid
Cancer Type
Melanoma
Therapy Types
Targeted Therapy
Regulatory
FDA
N/A
Regulatory Pathway: n/a
EMA
20.11.2015
Regulatory Pathway: standard approval
Availability in other countries
N/A
Focus Area
Cancer
ASMR
III
Medical Need
Partially met
SMR
IMPORTANT
Orphan Status
No